Paper Details

  1. Home
  2. Paper Details

Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.

Author: RutherfordGeorge W, SiegfriedNandi, SpauldingAlicen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Treatment with highly active antiretroviral therapy (ART) has significantly improved survival and health outcomes for people with HIV globally. Two common medications used in initial HIV treatment are zidovudine (AZT) and tenofovir (TDF), which both block the HIV virus from replicating.
Paper Details　
Original Abstract of the Article :
The introduction of highly active antiretroviral therapy (ART) as treatment for HIV infection has greatly improved mortality and morbidity for adults and children living with HIV around the world. Two of the most common medications given in first-line ART are the nucleoside reverse transcriptase inh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD008740

データ提供：米国国立医学図書館（NLM）

Tenofovir vs. Zidovudine: A Battle of the Nucleoside Reverse Transcriptase Inhibitors

In the ongoing fight against HIV, researchers continue to explore and refine treatment options to combat the virus and improve the lives of those living with HIV. This research examines the efficacy of two commonly used nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir and zidovudine, in combination with other antiretroviral medications as first-line treatment for HIV infection.

A Comparison of Antiretroviral Powerhouses: Tenofovir and Zidovudine

The researchers compared the effectiveness of tenofovir and zidovudine in combination with other antiretroviral medications in individuals newly diagnosed with HIV. The results show that both tenofovir and zidovudine are effective in reducing viral load and improving immune function, signifying their crucial role in HIV treatment regimens.

A Continuing Quest for Improved Treatments: Harnessing the Power of Antiretroviral Therapies

This research provides valuable insights into the ongoing development of effective antiretroviral therapies for HIV. As we continue to refine our understanding of the virus and its interaction with medications, we can strive to develop better treatment options that provide long-term benefits for individuals living with HIV.

Dr.Camel's Conclusion

Just as a camel's hump stores energy for long journeys across the desert, antiretroviral therapies provide a crucial source of support for individuals living with HIV. This research highlights the importance of continued research and development in this field to ensure optimal treatment outcomes.

Date :
  1. Date Completed 2010-11-30
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

20927777

DOI: Digital Object Identifier

10.1002/14651858.CD008740

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.